Effient Approval Shows Mark Of FDA Controls
This article was originally published in The Pink Sheet Daily
Postmarketing trials offer opportunity to investigate a possible means to control the bleeding caused by prasugrel, but REMS includes messaging aimed at limited off-label use.
You may also be interested in...
FDA Panel Will Have To Resolve Bleeding Risk With Merck’s Vorapaxar
Novel antiplatelet product has suffered from excess bleeding rates in clinical trials and is searching for an appropriate patient population, after initial hopes of being a blockbuster.
AstraZeneca Faces Uphill Battle In Talking U.S. Docs Into Using Brilinta
U.S. physicians say skepticism over the North American results in the pivotal PLATO study is one of many factors that’s been slowing adoption. Competition with low-cost generics is another.
Study Shows Effient Not Superior To Plavix, But Bleeding Risk Similar
A study published in the New England Journal of Medicine showed Effient was not superior to Plavix in treating patients who had not undergone revascularization.